Background
==========

Tumor necrosis factor alpha (TNF-α), an important proinflammatory cytokine, is produced by activated macrophages and exerts its effects by binding to its two cognate cell surface receptors, TNFRSF1A/TNFR1 (p55/60) and TNFRSF1B/TNFR2 (p75/80). TNF-α and its superfamily members are well-known to have both beneficial and harmful effects [@B1]. Although TNF-α was discovered as a cytokine that could kill tumor cells, TNF-α can also lead to the proliferation, invasion, and metastasis of tumor cells [@B1]. The activities of TNF-α were shown to be dependent on the expression of TNFRSF1A and TNFRSF1B, which have different intracellular domains and mediate unique as well as overlapping functions, including the activation of transcriptional activator nuclear factor kappa B (NF-κB) and programmed cell death [@B2]. Although TNFRSF1B cannot directly mediate apoptosis, TNFRSF1A was shown to modulate TNFRSF1A-induced apoptosis, and can directly activate NF-κB [@B1], [@B3]-[@B5]. TNF-α and TNFRSF1A may play important roles in esophageal squamous cell carcinoma (ESCC), TNFRSF1A was found to be strongly expressed in an esophageal carcinoma cell line, and silencing the expression of TNFRSF1A promoted cell proliferation and downregulated the apoptotic rate [@B6]. In addition, 5-fluorouracil (5-FU) is commonly used in combination therapy for ESCC, and TNF-α decreased the effect of 5-FU and increased the level of proliferation in esophageal carcinoma cell lines [@B7].

The*TNF-α* and *TNFRSF1A* genes are highly polymorphic, and several single nucleotide polymorphisms have been identified in these genes, which may contribute to differences in gene expression levels and transcription [@B8]-[@B18]. Some of these polymorphisms were recently shown to be related to tumor progression, metastasis, prognosis, and survival [@B19]-[@B22]. However, these studies included patients treated with surgery or neoadjuvant chemoradiotherapy (CRT); therefore, the association between these *TNF-α* and *TNFRSF1A* polymorphisms and the prediction of clinical outcome with definitive CRT in ESCC remains unknown.

Predicting therapeutic responses is important in definitive CRT prior to the initiation of treatment; we previously reported a significant correlation between clinical response and survival, and showed that the *TNFRSF1B* 1466A/G (rs1061624) genotype could predict clinical response with definitive 5-FU/cisplatin (CDDP)-based CRT in 46 male Japanese patients with ESCC [@B23]. Although these findings suggest that TNF-α and its receptors may play a critical role in clinical response and survival, to the best of our knowledge, no published study has investigated associations between the polymorphisms of *TNF-α* and *TNFRSF1A* genes and the prediction of clinical outcome in ESCC patients treated with definitive CRT. The *TNF-α* -1031T\>C (rs1799964), -863C\>A (rs1800630), -857C\>T (rs1799724), -308G\>A (rs1800629), -238G\>A (rs361525), *TNFRSF1A* -609G\>T (rs4149570), and 36A\>G (rs767455) genotypes were selected for genotyping because they affect expression or transcription and have been associated with tumor progression, metastasis, prognosis, or survival in cancer [@B8]-[@B22].

In this study, patients with ESCC were followed-up for 5 years after treatment with definitive 5-FU/CDDP-based CRT, and the effects of the *TNF-α* -1031T\>C, -863C\>A, -857C\>T, -308G\>A, -238G\>A, *TNFRSF1A* -609G\>T, and 36A\>G genotypes were retrospectively evaluated in terms of predicting long-term survival, clinical response, and severe acute toxicities.

Methods
=======

Ethics statements
-----------------

Studies have been performed to evaluate the effects of genetic polymorphisms on clinical response, survival or severe acute toxicities during treatment with definitive 5-FU/CDDP-based CRT in Japanese patients with ESCC [@B23]-[@B27]. They were conducted with the authorization of the Institutional Review Board (IRB) and followed the Medical Research Council guidelines of Kobe University. All patients agreed to the studies and preservation of genomic DNA for future investigations, and additional studies were again authorized by the IRB and followed the guidelines of Kobe University. Written informed consent was obtained from all participants prior to genotyping.

Patients and study protocol
---------------------------

Forty-six ESCC patients treated with definitive 5-FU/CDDP-based CRT between October, 2003 and June, 2006 at Kobe University Hospital, Japan, were followed-up for 5 years. Female patients were excluded because of differences in TNF-α levels between males and females [@B28]. The demographic and clinicopathological characteristics of 46 male Japanese ESCC patients are summarized in Table [1](#T1){ref-type="table"}, as reported previously [@B23]. Survival time was defined as the time from the initiation of treatment to death from any cause or to the last date of the confirmation of survival. Survival data were updated on June 25, 2011.

A course consisted of the continuous infusion of 5-FU at 400 mg/m^2^/day for days 1-5 and 8-12, the infusion of CDDP at 40 mg/m^2^/day on days 1 and 8, and external beam radiotherapy using megavoltage (≥6 MV) X-rays was administered at 2 Gy/day on days 1 to 5, 8 to 12, and 15 to 19 (a total dose of 60 Gy in 30 fractions), with a second course being repeated after a 2-week interval [@B29], [@B30]. The clinical target volume (CTV) for 60 Gy irradiation included the primary tumor plus a 5-cm craniocaudal margin, and metastatic lymph nodes plus a 1-cm margin. Planning target volume was defined as CTV plus 5- to 20-mm margins for uncertainty. Elective nodal irradiation (40 Gy) to the mediastinal and perigastric lymph nodes in all cases, cervical lymph nodes for an upper thoracic primary tumor, and celiac lymph nodes for a lower thoracic primary tumor was also performed. Three-dimensional computed tomography or X-ray simulation was performed, which allowed for two-dimensional anterior-posterior opposed fields and a bilateral oblique boost. Heterogeneity-uncorrected doses were used. Salvage surgery, endoscopic treatment, or another regimen of chemotherapy was scheduled if disease progression/recurrence was observed. Clinical response and severe acute toxicities; leucopenia, stomatitis, and cheilitis, were evaluated in a previous study [@B23]. Associations between the *TNF-α* and *TNFRSF1A* genotypes and clinical response, long-term survival, and severe acute toxicities were evaluated in this study. It should be noted that the patients participating in this study were the same as those in our previous report [@B23].

Data analysis and statistics
----------------------------

All values reported are the mean ± standard deviation (SD). Fisher\'s exact test and the log-rank test were used to evaluate the effects of genotypes on long-term survival. P values of less than 0.05 (two tailed) were considered to be significant.

Genomic DNA extraction and genotyping
-------------------------------------

Genomic DNA was isolated from whole blood using a Taq-Man^®^ Sample-to-SNP™ kit (Applied Biosystems, Foster City, CA, USA), according to the manufacturer\'s directions, and stored at -80°C until analysis. *TNF-α* and *TNFRSF1A* genotypes were determined in a TaqMan^®^ MGB probe-based polymerase chain reaction (PCR) using the 7900HT™ real-time PCR system (Applied Biosystems) and TaqMan^®^ SNP genotyping assays (Applied Biosystems). PCR was carried out according to the manufacturer\'s protocol. Negative controls containing H~2~O instead of DNA were added for each set of reactions to detect contamination.

Results
=======

The 5-year survival rate was 68.2 % (15/22) for patients with CR and 20.8 % (5/24) for those with non-CR, and survival depended on clinical response, i.e., CR or non-CR (P = 0.0025, Fisher\'s exact test; P = 0.0004, Log-rank test). A significant difference was observed in lymph node metastasis (P = 0.036, Fisher\'s exact test) between patients who survived 5 years or more and those who survived less than 5 years. The 5-year survival rate was 61.9 % (13/21) in N0.

Table [2](#T2){ref-type="table"} shows the association between the *TNF-α*and *TNFRSF1A* genotypes, and *TNF-α* -1031T\>C, -863C\>A, -857C\>T, -308G\>A, -238G\>A, *TNFRSF1A* -609G\>T, and 36A\>G genotypes and clinical response in ESCC patients. Among the 7 genotypes evaluated, the *TNF-α* -857C\>T genotype had a significant effect on clinical response (P = 0.010, Fisher\'s exact test).

The *TNF-α* and *TNFRSF1A* genotypes, and *TNF-α* -1031T\>C, -863C\>A, -857C\>T, -308G\>A, -238G\>A, *TNFRSF1A* -609G\>T, and 36A\>G genotypes had no effect on 5-year survival (data not shown). The 5-year survival rates were 55.6 % (15/27) and 26.3 % (5/19) in patients with CC^-857^ and CT^-857^ + TT^-857^, respectively, and the *TNF-α* -857C\>T genotype had no significant effect on 5-year survival (CC^-857^ vs. CT^-857^ + TT^-857^, P = 0.072, Fisher\'s exact test).

Figure [1](#F1){ref-type="fig"} shows the association between the *TNF-α* -857C\>T genotype and survival. The median overall survival time (±SE) was more than 60 months and 22.4 ± 8.0 months for patients with CC^-857^ and CT^-857^ + TT^-857^, respectively; however, the genotype could not predict survival (P = 0.070, Log-rank test).

The *TNF-α* and *TNFRSF1A* genotypes were not associated with severe acute leucopenia, stomatitis, or cheilitis (data not shown). In addition, these genotypes had no effect on the TNM classification or disease stage. These genotype frequencies followed the Hardy-Weinberg principle, analyzed by Fisher\'s exact test.

Discussion
==========

We examined the effects of 7 selected polymorphisms in *TNF-α* and *TNFRSF1A* on clinical response, long-term survival, and severe acute toxicities with definitive 5-FU/CDDP-based CRT in Japanese ESCC patients. We identified the *TNF-α* -857C\>T genotype as a new predictive genetic marker of clinical response to treatment; patients with the T-allele at position -857 in the *TNF-α* promoter had a poorer response, whereas no such association was found for*TNF-α* -1031T\>C, -863C\>A, -308G\>A, -238G\>A, *TNFRSF1A* -609G\>T, or 36A\>G (Table [2](#T2){ref-type="table"}). Clinical response was significantly correlated with long-term survival, whereas the *TNF-α* -857C\>T genotype was not. Long-term survival was determined by lymph node metastasis. The *TNF-α* -857C\>T genotype was independent of clinicopathological factors, TNM classification, and disease stage. None of the other polymorphisms of *TNF-α* and *TNFRSF1A* had any effect on clinical response, long-term survival, or severe acute leucopenia, stomatitis, and cheilitis.

The *TNF-α* gene is located on Chr 6p21, within the class III region of the major histocompatibility complex, between HLA-B and HLA-DR. TNF-α performs multiple functions in immunity, inflammation, differentiation, apoptosis, and the control of cell proliferation via NF-κB through the distinct receptors, TNFRSF1A and TNFRSF1B [@B1]. When a member of the TNF superfamily binds with TNFRSF1A, it results in receptor trimerization and the clustering of intracellular death domains as the extrinsic pathway of apoptosis, which leads to the induction of apoptosis via the activation of NF-κB and caspases [@B31]. In a previous *in vitro* study, TNF-α was shown to strongly increase the activity of NF-κB, decrease the effect of 5-FU, and increase the level of proliferation [@B7]. Several polymorphisms have been identified in the *TNF-α* gene, which may contribute to differences in gene expression levels [@B8]-[@B15]. These results suggest the possibility that if polymorphisms in the promoter region of *TNF-α* increase TNF-α production, tolerance to 5-FU may increase via the activation of NF-κB. In previous reports, the *TNF-α* -1031C allele, -863A allele, and -857T allele increased TNF-α production [@B11], [@B14], and patients in our study with the T-allele at position -857 in the *TNF-α* promoter had a poorer response than that of CC^-857^ patients. Our results are consistent with those of previous studies in which the *TNF-α* -857C\>T genotype could predict clinical response. Therefore, the *TNF-α* -857C\>T genotype has been proposed to be predictive of clinical response caused by increase tolerance to 5-FU. On the other hand, *TNF-α* -1031T\>C and -863C\>A were not associated with clinical response. This may have been because the effect of activation with *TNF-α* polymorphisms differed depending on the cell lines used and ethnicity, and a combination of these polymorphisms [@B8]-[@B15], [@B32]. Furthermore, TNF-α production was significantly increased by the*TNF-α* -857T allele alone, whereas the *TNF-α* -1031C allele and -863A allele required both mutations to increase TNF-α production in Japanese subjects [@B11], [@B32]. These findings suggest that the influence of the *TNF-α* -857C\>T polymorphism on Japanese patients may be higher than that of the -1031T\>C and -863C\>A polymorphisms. In a previous study, the *TNF-α* -857T allele showed better overall survival in gastric cancer [@B20], which was in contrast with our findings. However, this difference may exist due to the therapeutic methods used, surgical treatment, drugs administered, and different types of cancer. Therefore, the effect of the *TNF-α* -857C\>T genotype may be important in Japanese ESCC patients with definitive CRT.

The G to A nucleotide change at -308 and -238 altered the transcription factor binding site, resulting in the increased production of TNF-α [@B8], [@B9]. Furthermore, the -308A allele has been associated with poor performance status, lesions, and large-size tumors of head and neck squamous cell carcinoma [@B19], and also with the prevalence of the T4 stage of disease and distant metastasis of gastric cancer [@B21]. In our study, *TNF-α* -308G\>A and -238G\>A were not associated with clinical response, survival, or clinicopathological factors. Although our samples had few variants to evaluate the association between *TNF-α* -308G\>A and -238G\>A, and clinical outcomes, these frequencies were almost the same as previous reports on Japanese patients [@B11], [@B32]. These 2 polymorphisms may not have had a strong influence on Japanese ESCC patients with definitive CRT. More studies with a larger sample size are needed to clarify the effects of these 2 polymorphisms. On the other hand, in spite of the clinical response associated with survival, the *TNF-α* -857C\>T genotype could not predict survival, which may have been due to the small sample size (N = 46). Here, 5 of 7 patients with CR appeared to have died because of late toxicities and other cancer deaths. This may have affected the association between the*TNF-α* -857C\>T genotype and long-term survival.

The *TNFRSF1A* -609G/T and 36A/G genotypes were also not associated with clinical response or long-term survival. TNFRSF1A may play an apoptosis-mediating role in esophageal carcinoma [@B6], and *TNFRSF1A* -609G/T was previously shown to increase TNFRSF1A mRNA expression in subjects including patients with invasive pulmonary aspergillosis [@B17]. However, another report showed the decreased expression of *TNFRSF1A* -609G/T in hepatocellular carcinoma cells [@B16]; therefore, further studies are needed to clarify the effect of *TNFRSF1A* -609G/T. In addition, the *TNFRSF1A* -609T allele was associated with poor overall survival and disease-free survival in non-small-cell lung cancer [@B22]; however, approximately half of these patients did not receive chemotherapy. *TNFRSF1A* 36A\>G was previously suggested to be a potential exonic splicing enhancer site for three splicing factors, SRp55, SF2/ASF2, and SF2/ASF1 [@B18]; however, its effect on cancer remains unknown. TNFRSF1B has a higher binding affinity to TNF-α than TNFRRSF1A [@B2], and NF-κB activity was mediated not only by TNFRSF1A, but also by TNFRSF1B. The expression levels of the *TNFRSF1B* gene were higher in the colorectal cancer specimens of non-responding patients to 5-FU than in those from responding patients [@B33]. In addition, a high concentration of TNF-α induced responses through TNFRSF1A, which transmits signals promoting growth inhibition and cell death, while a low concentration stimulated responses through the TNFRSF1B-NF-κB signaling pathway, which stimulates cell proliferation [@B34], [@B35]. Moreover, the results of our previous study showed the relationship between *TNFRSF1B* 1466A\>G and clinical response in ESCC [@B23], and suggested that the relationship of TNF-α and TNFRSF1B to clinical response in ESCC with definitive CRT may be more important than that of TNFRSF1A to TNF-α concentrations and the effect of 5-FU.

In conclusion, the *TNF-α* -857C\>T genotype was shown to be a new predictive genetic marker of clinical response and may be predictive of long-term survival following treatment with definitive 5-FU/CDDP-based CRT. This is the first study to identify the association between *TNF-α* polymorphisms and clinical response with definitive CRT in Japanese ESCC patients. Further clinical studies with a larger number of cases, in which the relationship between long-term survival and clinical response with polymorphism-dependent TNF-α expression levels, including the *TNF-α* and *TNFRSF1B* genotypes, is examined, are needed to clarify the effects of this genotype.
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Demographic and clinicopathological characteristics of 46 Japanese patients with esophageal squamous cell carcinoma.
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a\) Values represent the mean ± SD, with the range in parentheses.

###### 

Effect of the *TNF-α* and *TFNRSF1A* genotypes on clinical response in 46 Japanese patients with esophageal squamous cell carcinoma.
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Genotype frequencies followed the Hardy-Weinberg principle. b) Complete response vs. not complete response.
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